Table III.
NPM1 mutations and outcomes in acute myeloid leukemia.
| Author (Refs.) | NPM1 status | Subjects (n) | CR (%) | HR for OS | 95% CI for OS | HR for DFS | 95% CI for DFS |
|---|---|---|---|---|---|---|---|
| Thiede et al (14) | NPM1-wt | 1077 | 41.60a | 1.00 | Reference | 1.00 | Reference |
| NPM1-mt | 408 | 58.60 | 0.73 | 0.58–0.91 | 0.75 | 0.54–1.04 | |
| Döhner et al (15) | NPM1-wt | 155 | 68.50a | 1.00 | Reference | NR | NR |
| NPM1-mt | 145 | 86.00 | 0.44 | 0.30–0.66 | NR | NR | |
| Schnittger et al (16) | NPM1-wt | 189 | 54.70a | NR | NR | 1.00 | Reference |
| NPM1-mt | 212 | 70.50 | NR | NR | 0.53 | 0.35–0.79 | |
| Suzuki et al (19) | NPM1-wt | 141 | 68.80a | NR | NR | NR | NR |
| NPM1-mt | 49 | 85.70 | NR | NR | NR | NR | |
| Verhaak et al (13) | NPM1-wt | 180 | NA | 1.00 | Reference | 1.00 | Reference |
| NPM1-mt | 95 | NA | 0.49 | 0.33–0.72 | 0.52 | 0.34–0.80 | |
| Mullighan et al (18) | NPM1-wt | 87 | 85.06 | NA | NA | NA | NA |
| NPM1-mt | 6 | 100.00 | NA | NA | NA | NA | |
| Gale et al (20) | NPM1-wt | 714 | NA | 1.00 | Reference | 1.00 | Reference |
| NPM1-mt | 503 | NA | 0.67 | 0.58–0.77 | 0.72 | 0.62–0.84 | |
| Becker et al (21) | NPM1-wt | 65 | 47.69a | 1.00 | Reference | 1.00 | Reference |
| NPM1-mt | 83 | 84.34 | 0.43 | 0.30–0.63 | 0.48 | 0.29–0.78 |
NPM1, nucleophosmin 1; CR, complete remission; HR, hazard ratio; 95% CI, 95% confidence interval; OS, overall survival; NR, not reported; NA, not assessed; DFS, disease-free survival; NPM1-mt, NPM1-mutation type; NPM1-wt, NPM1-wild-type. Statistically significant difference (aP<0.05).